Răzvan Cristescu

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Technical evaluation of commercially available homologous recombination deficiency assays using MyChoice CDx as reference in ovarian cancer

  Gynecologic Oncology · 2026-06-25

• Real-world effectiveness of pembrolizumab among patients with TMB-H advanced solid tumors.

  Journal of Clinical Oncology · 2026-05-28

• Abstract LB490: Preclinical evaluation of the nectin-4 antibody-drug conjugate MK-3120 (SKB410) in a panel of solid-tumor patient-derived xenograft models

  Cancer Research · 2026-04-17

• Abstract 1008: Effect of the KRAS G12C inhibitor MK-1084 on circulating tumor DNA levels in participants with KRAS G12-mutated tumors

  Cancer Research · 2026-04-03

• Genomic assessment of acquired mutations in participants with CLL/SLL treated with nemtabrutinib in the Phase 2 bellwave-003 study

  Blood · 2025-11-03 · 1 citations

• Prevalence of therapeutic or disease-relevant oncogenic alterations: An analysis of the AACR Project GENIE Biopharma Cooperative bladder cancer cohort

  Urologic Oncology Seminars and Original Investigations · 2025-10-16

• Association of potential biomarkers with clinical outcomes in metastatic triple-negative breast cancer treated with pembrolizumab or chemotherapy

  npj Breast Cancer · 2025-10-02 · 2 citations

• Corrigendum to “Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC [JTO Clinical and Research Reports Vol. 4 No. 1: 100431]

  JTO Clinical and Research Reports · 2025-09-02

• 2789P Real-world molecular epidemiology study of select biomarkers in extensive-stage small-cell lung cancer (ES-SCLC)

  Annals of Oncology · 2025-09-01

• Abstract LB1-07: Exploratory Biomarker Analysis of the Phase 3 KEYNOTE-522 Study of Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for Early-Stage TNBC

  Clinical Cancer Research · 2025-06-13 · 9 citations

• Prevalence of androgen receptor ligand-binding domain mutations (AR-LBDm) in circulating tumor DNA (ctDNA) versus tissue biopsies in participants (pts) with metastatic castration-resistant prostate cancer (mCRPC) and other tumor types.

  Journal of Clinical Oncology · 2025-05-28

• Assessment of Circulating Tumor DNA Burden in Patients With Metastatic Gastric Cancer Using Real-World Data

  JCO Precision Oncology · 2025-05-01 · 1 citations

• Erratum: Genomic Landscape of Late-Stage Gastric Cancer: Analysis From KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Studies

  JCO Precision Oncology · 2025-04-01

• Genomic Landscape of Late-Stage Gastric Cancer: Analysis From KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Studies

  JCO Precision Oncology · 2025-03-21 · 5 citations

• Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 study

  Breast Cancer Research · 2025-03-11 · 5 citations

• Characterization of circulating tumor DNA (ctDNA) burden and its association with real-world overall survival among prostate cancer (PC) patients.

  Journal of Clinical Oncology · 2025-02-10

• Real-world prevalence and outcomes of androgen receptor ligand-binding domain mutations in prostate cancer.

  Journal of Clinical Oncology · 2025-02-10 · 1 citations

• Prevalence of Homologous Recombination Repair Mutations and Association with Clinical Outcomes in Patients with Solid Tumors: A Study Using the AACR Project GENIE Dataset

  Cancers · 2025-02-08

• Biomarker analyses from the phase III randomized CLEAR trial: lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma

  Annals of Oncology · 2024-12-11 · 17 citations

• Supplementary Table S2 from Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma

  2024-12-02